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Introduction
Translational control and regulation of cell size are essential 
cellular processes that govern the development and homeo-
stasis of cells and tissues (Ruvinsky and Meyuhas, 2006). The 
protein synthesis machinery has been largely considered an 
autonomous entity whose overall output is subject to a limited 
number of control mechanisms. However, several compo-
nents of the translational machinery and, consequently, the 
process of protein biosynthesis are controlled by signaling 
pathways and transcriptional regulation (Hay and Sonenberg, 
2004). In addition, changes in the control of translation are 
associated with carcinogenesis. Specifi cally, ribosome func-
tion can be modulated by tumor suppressors and oncogenes, 
whereas certain signaling pathways enhance the translational 
capacity of the cell. Deregulation of one or more steps that 
control protein biosynthesis has been associated with altera-
tions in cell cycle progression and cell growth (Ruggero and 
Pandolfi , 2003).
Activation of mammalian target of rapamycin (mTOR) 
has emerged as a regulatory mechanism that is conserved from 
yeast to mammals in the control of protein biosynthesis and 
cell size (Wullschleger et al., 2006). mTOR is a large serine/
threonine protein kinase that is found in two distinct multi-
protein complexes: mTOR complex 1 (mTORC1; containing 
mLST8 and raptor), which has been implicated in translational 
regulation (Wullschleger et al., 2006), and mTORC2 (containing 
mLST8, mSin1, and rictor; Sarbassov et al., 2004; Frias et al., 
2006). Rapamycin in complex with FKBP12 interacts with 
mTOR and inhibits its activity when mTOR is part of mTORC1 
(Wullschleger et al., 2006). mTOR activity is increased in many 
tumors, which is consistent with its pivotal role in protein bio-
synthesis, and specifi c inhibition of mTOR function through the 
use of rapamycin analogues is considered a promising avenue 
for cancer treatment (Faivre et al., 2006; Hynes and Boulay, 
2006; Smolewski, 2006).
The best-characterized effectors of mTOR in the rapamycin-
sensitive complex are S6 kinase 1 (S6K1) and the eukaryotic 
initiation factor 4E–binding protein 1 (4E-BP1). Phosphorylation 
of S6K1 by mTOR enhances the translational capacity by acting 
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 Epithelial to mesenchymal transition (EMT) occurs during development and cancer progression to metastasis and results in enhanced cell motility and 
invasion. Transforming growth factor-β (TGF-β) induces 
EMT through Smads, leading to transcriptional regulation, 
and through non-Smad pathways. We observe that TGF-β 
induces increased cell size and protein content during 
EMT. This translational regulation results from activation 
by TGF-β of mammalian target of rapamycin (mTOR) 
through phosphatidylinositol 3-kinase and Akt, leading to 
the phosphorylation of S6 kinase 1 and eukaryotic initiation 
factor 4E–binding protein 1, which are direct regulators 
of translation initiation. Rapamycin, a specifi c inhibitor of 
mTOR complex 1, inhibits the TGF-β–induced translation 
pathway and increase in cell size without affecting the 
EMT phenotype. Additionally, rapamycin decreases the 
migratory and invasive behavior of cells that accom-
pany TGF-β–induced EMT. The TGF-β–induced translation 
pathway through mTOR complements the transcription 
pathway through Smads. Activation of mTOR by TGF-β, 
which leads to increased cell size and invasion, adds to 
the role of TGF-β–induced EMT in cancer progression and 
may represent a therapeutic opportunity for rapamycin 
analogues in cancer.
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on translation initiation complex assembly (Hay and Sonenberg, 
2004; Holz et al., 2005). Phosphorylation of 4E-BP1 by mTOR 
induces the dissociation of eukaryotic initiation factor 4E from 
4E-BP1, which enhances the cap-dependent initiation of mRNA 
translation (Hay and Sonenberg, 2004).
mTOR serves as a sensor and integrator of multiple 
stimuli induced by growth factors, nutrients, energy, or stress. 
The best-characterized signaling pathway that regulates 
mTOR activity in mTORC1 is initiated by the activation of 
phosphatidylinositol 3-kinase (PI3K), which enhances the 
phosphorylation of Akt (also known as PKB; Fingar and Blenis, 
2004; Hay and Sonenberg, 2004). Akt phosphorylation inacti-
vates the tuberous sclerosis complex (TSC) formed by hamartin 
(TSC1) and tuberin (TSC2; Manning and Cantley, 2003), 
leading to accumulation of the GTP-bound form of the small 
G protein Rheb that activates mTOR (Fingar and Blenis, 2004). 
The pathway from PI3K to mTOR is up-regulated in many 
cancers, as refl ected by the increased phosphorylation of 
PI3K and Akt, which correlates with increased mTOR activity 
(Guertin and Sabatini, 2005; Faivre et al., 2006). Growth factors 
that act through tyrosine kinase receptors have the ability to 
activate PI3K. Most prominent among these are insulin and 
insulin-like growth factor-1 (IGF-1; Grimberg, 2003). The up-
regulation of IGF-1 expression and autocrine responses in many 
tumors may well be a major factor in the increased PI3K signaling 
and mTOR activity in cancers. Inhibitors of PI3K are accord-
ingly pursued for targeted cancer therapy (Kim et al., 2005; 
Faivre et al., 2006).
TGF-β, a secreted cytokine, regulates a variety of pro-
cesses in development and cancer and exerts many autocrine 
activities. The expression of TGF-β, specifi cally TGF-β1, is 
up-regulated in many, if not most, cancers and is thought to play 
a key role in cancer progression (Bierie and Moses, 2006). In 
early tumor progression, deregulation of TGF-β signaling leads 
to a loss of its autocrine antiproliferative effect, resulting in 
increased cell proliferation. However, the increased TGF-β 
expression by tumor cells provides distinct advantages for cancer 
progression (e.g., by inducing localized immunosuppression 
or enhanced angiogenesis; Bierie and Moses, 2006). In addi-
tion, this increased TGF-β expression benefi ts cancer progres-
sion through autocrine effects on the tumor cells. Specifi cally, 
TGF-β can induce an epithelial to mesenchymal transition 
(EMT) of carcinoma cells, which leads to invasion and meta-
stasis (Derynck et al., 2001; Zavadil and Bottinger, 2005; Thiery 
and Sleeman, 2006). EMT is a complex process that involves 
cytoskeletal remodeling, cell–cell and cell–matrix adhesion, 
and transcriptional regulation, leading to the transition from 
a polarized epithelial phenotype to an elongated fi broblastoid 
phenotype (Zavadil and Bottinger, 2005; Thiery and Sleeman, 
2006). A disassembly of cell–cell junctions, including the re-
localization of E-cadherin and zonula occludens-1 (ZO-1), oc-
curs during EMT and allows for an increase in cell motility. As 
a result of EMT, the fi broblastoid cells degrade the extracel-
lular matrix and show invasive behavior. The key role of this 
TGF-β–mediated process in cancer is illustrated by the ability 
of TGF-β inhibitors to diminish cancer progression and meta-
stasis (Arteaga, 2006).
TGF-β signals through a complex of two types of serine/
threonine kinase receptors. Upon ligand binding, the type II re-
ceptors activate the type I receptors, which recruit and activate 
the intracellular mediators Smad2 and Smad3. Smad2 and 
Smad3 combine with Smad4 to form complexes that translocate 
into the nucleus to activate or repress gene expression (Shi and 
Massagué, 2003; Feng and Derynck, 2005). Increasing evidence 
shows that Smad signaling leading to transcription responses 
is complemented by non-Smad signaling mechanisms that are 
also activated by TGF-β (Derynck and Zhang, 2003; Moustakas 
and Heldin, 2005). TGF-β–induced EMT, which is largely stud-
ied using NMuMG epithelial cells as a model, integrates Smad 
as well as non-Smad signaling, including signaling through small 
GTPases and the Erk and p38 MAPK pathways (Moustakas and 
Heldin, 2005; Zavadil and Bottinger, 2005).
In our studies of TGF-β–induced EMT using NMuMG 
cells as a model, we observed that the typical loss of the epithe-
lial phenotype with concomitant acquisition of the spindle-shaped 
fi bro blastoid phenotype was accompanied by an increase in cell 
size and protein content. The TGF-β–induced increases in cell 
size and protein synthesis correlated with a rapid activation of 
mTOR and phosphorylation of its effectors S6K1 and 4E-BP1 
through the PI3K–Akt pathway. Inhibition of mTOR by rapamy-
cin blocked the TGF-β–induced increases in cell size and protein 
synthesis without affecting the EMT phenotype and inhibited cell 
migration, adhesion, and invasion. Although these results estab-
lish mTOR activation as a novel non-Smad TGF-β signaling 
pathway, they also reveal the direct regulation of protein synthesis 
by TGF-β as an effector pathway that complements the transcrip-
tional regulation through Smads. The autocrine response of cells 
to TGF-β–induced mTOR activation and protein synthesis may 
represent a novel mechanism through which the increased TGF-β 
expression in tumor cells contributes to cancer progression.
Results
The TGF-𝛃–induced EMT is associated with 
an increase in cell size and protein content
Murine mammary epithelial NMuMG cells are known to undergo 
an EMT that is readily apparent at 36 h after TGF-β treatment 
(Miettinen et al., 1994). As a result of EMT, the cells adopt a 
spindlelike shape with actin reorganization and E-cadherin de-
localization from the adherens junctions (Fig. 1, A and B). To bet-
ter characterize the EMT in NMuMG cells, we used time-lapse 
microscopy during the fi rst 36 h after adding TGF-β. No major 
change in cell morphology was apparent during the fi rst 24 h 
of TGF-β treatment, and the treated cells elongated between 
24 and 36 h after adding TGF-β (Videos 1 and 2, available at 
http://www.jcb.org/cgi/content/full/jcb.200611146/DC1).
Concomitantly with the change in phenotype, the cells ap-
peared to increase in size (Fig. 1, A and B). To assess whether this 
was indeed the result of an increase in cell size rather than a more 
spread phenotype, we evaluated the size of treated and untreated 
cells by fl ow cytometry using forward scatter as the parameter 
indicative of cell size. Furthermore, because cell size varies with 
cell cycle progression (Grebien et al., 2005), we measured the 
size of only the cells in the G1 phase. At 24 h after adding TGF-β, 
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no difference in cell size was apparent between TGF-β–treated 
and untreated NMuMG cells (unpublished data). In contrast, after 
48 h, TGF-β–treated cells consistently showed an increase in cell 
size of 10–30% (Fig. 1, C and D). We observed that the TGF-β–
 treated cells were also larger in the S and G2/M phases of the 
cell cycle (unpublished data). After EMT, the removal of TGF-β 
resulted in enhanced proliferation and mesenchymal to epithelial 
transition (unpublished data). This reversibility of the phenotype 
suggests that the increase in cell size did not result from senes-
cence, which is consistent with the lack of senescence-associated 
β-galactosidase staining (Dimri et al., 1995; unpublished data).
Because changes in cell size often correlate with differ-
ences in protein content, we measured the protein content in 
untreated and TGF-β–treated NMuMG cells. TGF-β increased 
the protein synthesis in NMuMG cells from 20 to 60% after 
24 h (Fig. 1 E), whereas no effect of TGF-β on protein syn-
thesis was observed after 6 and 12 h (not depicted). To con-
fi rm the effect of TGF-β on protein synthesis, we measured the 
incorporation of 35S-labeled methionine into newly synthesized 
proteins at 24 h after TGF-β treatment. As shown in Fig. 1 F, 
we found that TGF-β induces an increase in the synthesis of 
new proteins.
Figure 1. Increase in cell size and protein content during the TGF-𝛃–induced EMT in NMuMG cells. (A) Cells were treated or not treated with TGF-β for 48 h 
before photography. Original magnifi cation was 40×. See Videos 1 and 2 (available at http://www.jcb.org/cgi/content/full/jcb.200611146/DC1). 
(B) Cells treated or not treated with TGF-β for 48 h were stained for F-actin or E-cadherin. Nuclei were visualized using DAPI staining. Original magnifi cation 
was 100×. (C) After 48 h of TGF-β treatment or no treatment, the cell cycle distribution was determined by fl ow cytometry analysis (left), and the size distri-
bution of cells in G1 phase was determined by fl ow cytometry using the forward scatter parameter (FSC; right). (D) Quantifi cation of the forward scatter nor-
malized to untreated cells shows relative mean values of one representative experiment out of seven with SD (error bars) for duplicates (*, P < 0.05 vs. 
control). (E) 24 h after adding TGF-β, the total protein content was measured and normalized for cell number, as shown relative to untreated cells. One rep-
resentative experiment out of fi ve is shown with SD for triplicates (**, P < 0.01 vs. control). (F) 24 h after adding TGF-β, cells were [35S]-methionine/cysteine 
labeled, and trichloroacetic acid–precipitated proteins were quantifi ed. The newly synthesized protein value is normalized to the cell number and shown rela-
tive to untreated cells. One out of two representative experiments is shown with SD for triplicates (*, P < 0.05 vs. control). Bars (A), 50 μm; (B) 20 μm.
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TGF-𝛃 activates the mTOR pathway
mTOR signaling has been implicated in the control of protein 
synthesis through the phosphorylation of S6K1 and 4E-BP1 
(Hay and Sonenberg, 2004). Because TGF-β increases protein 
synthesis, we explored the effect of TGF-β on S6K1 phosphor-
ylation in NMuMG cells. Immunoblot analyses with antibodies 
specifi c to the phosphorylated form of S6K1 showed that TGF-β 
induced the phosphorylation of S6K1 within 1 h after adding 
TGF-β, reaching maximum phosphorylation at 24 h (Fig. 2 A). 
TGF-β also induced the phosphorylation of 4E-BP1 with a 
peak at 1 h of treatment, as apparent from immunoblot analyses 
using an antibody to phospho-Ser65 4E-BP1 (Fig. 2 B). The 
TGF-β–induced phosphorylation of 4E-BP1 appeared more 
transient than the S6K1 phosphorylation and was no longer 
apparent at 24 h.
In response to insulin or other inducers of protein synthesis, 
the phosphorylation of S6K1 and 4E-BP1 results from mTOR 
activation (Hay and Sonenberg, 2004). It has been shown that 
the phosphorylation of mTOR on Ser2448 correlates with its 
activation in response to insulin or growth factor stimulation 
(Fingar and Blenis, 2004). Therefore, we examined whether 
mTOR is phosphorylated on Ser2448 in response to TGF-β using a 
phospho-Ser2448–specifi c antibody. As shown in Fig. 2 C, TGF-β 
induced the phosphorylation of mTOR with kinetics similar 
to the TGF-β–induced phosphorylation of S6K1 and 4E-BP1. 
To establish a causal relationship, we examined the effect of 
rapamycin, an inhibitor of mTOR activation, on S6K1 phosphor-
ylation in response to TGF-β. As shown in Fig. 2 D, TGF-β did 
not induce S6K1 phosphorylation in the presence of rapamycin 
after 1 h, implicating mTOR activation in TGF-β–induced S6K1 
phosphorylation. The effect of rapamycin on TGF-β–induced 
S6K1 phosphorylation was still apparent at 36 h (Fig. 2 D).
mTOR and S6K1 activation by TGF-𝛃 
is mediated by T𝛃RI, PI3K, and Akt
mTOR activation in response to tyrosine kinase receptors has 
been shown to result from the activation of PI3K, which, in turn, 
leads to the activation of Akt (Hay and Sonenberg, 2004). We 
investigated whether the activation of mTOR by TGF-β occurs 
through the activation of PI3K, which then activates Akt. Because 
PI3K activates Akt through phosphorylation on Ser473, we exam-
ined the level of Akt activation in response to TGF-β in NMuMG 
cells using an antibody against phospho-Ser473 Akt. We found 
that TGF-β led to Akt phosphorylation after 30 min with a peak 
at 1 h (Fig. 3 A, top). This activation was inhibited by LY294002 
or wortmannin, which are two inhibitors of PI3K, indicating that 
the TGF-β–induced phosphorylation of Akt occurred through 
the activation of PI3K (Fig. 3 B, top). Stimulation of NMuMG 
cells with TGF-β also resulted in the phosphorylation of Smad3. 
A peak level for TGF-β–induced Smad3 phosphorylation was 
reached after 30 min of stimulation (Fig. 3 A, bottom). Thus, 
Akt activation in response to TGF-β occurred with similar kinet-
ics, albeit possibly somewhat slower than Smad3 activation. The 
PI3K inhibitors did not affect the TGF-β–induced phosphoryla-
tion of Smad3 (Fig. 3 B, bottom).
TGF-β–induced Smad signaling results from activation of 
the type I TGF-β receptor (TβRI), which acts epistatically down-
stream from the type II receptor (a result of TβRII-mediated 
activation of the TβRI kinase). Whereas Smads are activated by 
TβRI, several responses have recently been directly linked to 
type II receptors without the functional requirement of the TβRI 
kinase activity (Ozdamar et al., 2005). Therefore, we examined 
whether the TGF-β–induced activation of Akt depended directly 
on the kinase activity of TβRI using the kinase inhibitor 
SB431542, which specifi cally binds the ATP-binding site of 
TβRI and does not inhibit TβRII. As shown in Fig. 3 C, SB431542 
prevented the TGF-β–induced activation of Akt as well as Smad3 
phosphorylation. We conclude that TGF-β induces Akt activation 
through activation of the TβRI kinase.
To further defi ne the activating pathway leading to S6K1 
and 4E-BP1 phosphorylation upon TGF-β treatment, we ex-
amined whether the phosphorylation of S6K1 and 4E-BP1 in 
response to TGF-β requires the activation of PI3K. To this end, 
we examined the effect of TGF-β on the phosphorylation of 
S6K1 and 4E-BP1 in the absence or presence of wortmannin, 
an inhibitor of PI3K, using insulin as a positive control to induce 
Figure 2. TGF-𝛃 induces mTOR, S6K1, and 4E-BP1 phosphorylation. 
(A–C) NMuMG cells were treated with TGF-β for the indicated times before 
lysis, SDS-PAGE, and immunoblotting (IB) with an antibody to phospho-S6K1 
(A), phospho–4E-BP1 or α-tubulin (B), or phospho-mTOR (C). The phospho-
S6K1 and phospho-mTOR immunoblots were reprobed with S6K1 and 
mTOR antibody, respectively. (D) NMuMG cells were pretreated without or 
with rapamycin for 1 h, and TGF-β was added for the indicated times. Cell 
lysates were separated by SDS-PAGE and immunoblotted with phospho-
S6K1 antibody, stripped, and reblotted with S6K1 antibody.
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S6K1 and 4E-BP1 phosphorylation. Wortmannin inhibited 
the TGF-β–induced S6K1 and 4E-BP1 phosphorylation sim-
ilar to its effect on insulin-induced phosphorylation and to the 
same extent as rapamycin, the inhibitor of mTOR (Fig. 3 D). 
Moreover, activation of Akt was required for TGF-β–induced 
S6K1 phosphorylation as for insulin-induced S6K1 phosphor-
yl ation because expression of an Akt mutant, in which both 
Ser473 and Thr308 have been replaced by alanines, blocked 
TGF-β–induced S6K1 phosphorylation (Fig. 3 E). This Akt-AA 
mutant has previously been shown to prevent Akt activation 
through dominant-negative interference (Stokoe et al., 1997). 
Together, these data illustrate that TGF-β induces the activation 
of mTOR and phosphorylation of its downstream targets S6K1 
and 4E-BP1 through the activation of PI3K and Akt. Rapamycin 
decreases the TGF-β–dependent increase of cell size and pro-
tein synthesis.
Figure 3. The TGF-𝛃–induced mTOR pathway is activated by T𝛃RI, PI3K, and Akt. (A) NMuMG cells were stimulated with TGF-β for the indicated times. 
Cell lysates were separated by SDS-PAGE and subjected to immunoblotting (IB) with phospho-Akt or phospho-Smad3/Smad1 antibodies and subsequent 
reblotting with Akt or Smad3 antibodies, respectively. (B) NMuMG cells were pretreated without or with wortmannin or LY294002 for 1 h, and TGF-β was 
added or not added to the medium for 1 h. Cell lysates were immunoblotted with antibodies to phospho-Akt or phospho-Smad3/Smad1 and reblotted with 
antibodies to Akt or Smad3, respectively. (C) NMuMG cells were treated without or with SB431542 for 1 h, and TGF-β was added or not added to the me-
dium for 1 h. Cell lysates were immunoblotted with antibodies to phospho-Akt or phospho-Smad3/Smad1 and reprobed with antibodies to Akt or Smad3, 
respectively. (D) NMuMG cells were treated with or without rapamycin or wortmannin for 1 h, and TGF-β or 5 μg/ml insulin was added or not added to 
the medium for 1 h. Cell lysates were immunoblotted with antibodies to phospho-S6K1 or 4E-BP1 and reprobed with S6K1 antibody. (E) NMuMG cells 
were transfected to express a dominant-negative Akt mutant with Ser473 and Thr308 substituted by alanines. Cells were stimulated or not stimulated with 
TGF-β or 5 μg/ml insulin for 1 h. Cell lysates were immunoblotted with antibodies to phospho-S6K1, Akt, or phospho-Smad3/Smad1; phospho-S6K1 and 
phospho-Smad3/Smad1 immunoblots were reprobed with S6K1 or Smad3 antibodies, respectively.
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The increase in cell size and protein synthesis concomi-
tantly with activation of the mTOR–S6K1 pathway in response 
to TGF-β raises the question of how much the activation of 
mTOR accounts for the TGF-β–induced increase in cell size 
and protein synthesis. Therefore, we examined the effect of 
rapamycin on the TGF-β–induced cell size increase. Rapamycin 
inhibited the TGF-β–induced increase in cell size, as assessed 
by forward scatter in FACS analysis (Fig. 4 A). Because auto-
crine TGF-β signaling occurs in most, if not all, cells in culture, 
including NMuMG cells, we set out to defi ne the contribution 
of autocrine TGF-β signaling by assessing in parallel the cellu-
lar response to SB431542, which prevents the TGF-β–induced 
activation of Akt and is expected to block autocrine TGF-β 
signaling. As shown in Fig. 4 B, SB431542 treatment in the ab-
sence of added TGF-β resulted in a decreased cell size. These 
results suggest that autocrine TGF-β signaling contributes to the 
control of cell size.
Similar experiments were performed to evaluate the effects 
of rapamycin and SB431542 on protein synthesis. Consistent with 
the results on cell size, rapamycin and SB431542 both inhibited 
the TGF-β–induced increase in protein content (Fig. 4, C and D). 
Furthermore, SB431542 moderately decreased the protein content 
of NMuMG cells in the absence of added TGF-β. We conclude 
that similar to the control of cell size, autocrine TGF-β signaling 
through mTOR contributes to the control of protein synthesis.
Rapamycin does not affect 
the TGF-𝛃–induced EMT phenotype
We compared the effects of rapamycin and SB431542 on TGF-β–
induced EMT. As expected, inhibition of the kinase activity of 
TβRI using SB431542 prevented TGF-β from inducing EMT, 
and the cells maintained their epithelial phenotype. In contrast, 
rapamycin did not affect TGF-β–induced EMT. Thus, the cells 
acquired their elongated shape with a loss of E-cadherin local-
ization at cell–cell junction and actin reorganization (Fig. 5 A). 
EMT is accompanied by the disruption of ZO-1 from tight junc-
tions and increased N-cadherin and fibronectin expression 
(Bhowmick et al., 2001; Thiery and Sleeman, 2006). Rapamycin 
did not affect the changes in ZO-1, fi bronectin, and N-cadherin 
subcellular localization that accompanied TGF-β–induced 
EMT as assessed by immunofl uorescence nor did it affect the 
epithelial phenotype in the absence of added TGF-β (Fig. 5 B). 
Because rapamycin blocked the TGF-β–induced increase in 
protein content and size, the cells that underwent EMT in 
Figure 4. Effect of rapamycin on TGF-𝛃–induced cell size and protein synthesis of NMuMG cells. (A and B) Cells were pretreated with or without rapamycin 
(A) or SB431542 (B) for 1 h, and TGF-β was added or not added to the medium for 48 h. The cell cycle distribution was determined by fl ow cytometry 
(left), and the size distribution of cells in G1 phase was determined by fl ow cytometry using the forward scatter parameter (FSC; right). The numbers repre-
sent the mean forward scatter percentage of cell size increase (+) or decrease (−) normalized to untreated cells. One representative experiment out of two 
independent experiments is shown with SD (error bars) for triplicates. (C and D) Cells were pretreated with or without rapamycin (C) or SB431542 (D) for 
1 h, and TGF-β was added or not added to the medium. After 24 h, the cells were trypsinized, and the cell number was determined. The total protein con-
tent normalized for cell number is shown relative to untreated cells. One representative experiment out of two independent experiments is shown with SD 
for triplicates (**, P < 0.01).
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response to TGF-β and in the presence of rapamycin were 
smaller than in the absence of rapamycin (Fig. 4, A and C). Our 
results indicate that inhibition of the mTOR pathway does not 
affect the morphological changes associated with EMT but in-
hibits the TGF-β–induced increase in protein content and cell 
size that accompanies EMT of NMuMG cells.
Figure 5. Effect of rapamycin on TGF-𝛃–
induced EMT. (A) NMuMG cells were treated 
with or without rapamycin or SB431542 for 1 h, 
and TGF-β was added or not added to the 
medium. After 48 h, the cells were stained for 
F-actin and E-cadherin. DAPI was used to stain 
the nuclei. Original magnifi cation was 100×. 
(B) Cells were treated with or without rapamy-
cin for 1 h, and TGF-β was added or not added 
to the medium. After 48 h, the cells were 
stained for F-actin, ZO-1, N-cadherin, or fi bro-
nectin. DAPI was used to stain the nuclei. Orig-
inal magnifi cation was 100×. Bars (A), 20 μm; 
(B) 10 μm.
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Activation of mTOR during TGF-𝛃–induced 
EMT in human HaCaT cells
To assess whether the data using murine NMuMG cells can be 
extended to other cell systems, we evaluated the human HaCaT 
keratinocytes, which also undergo EMT in response to TGF-β 
(Zavadil et al., 2001). As shown in Fig. 6 A, TGF-β induced 
the elongated morphology characteristic of EMT after 72 h of 
TGF-β treatment. The idea that HaCaT cells underwent EMT in 
response to TGF-β was also apparent from the fi lamentous actin 
(F-actin) stress fi ber formation and E-cadherin relocalization 
from the junctions (Fig. 6 C).
As in NMuMG cells, TGF-β induced the phosphorylation 
of S6K1 in HaCaT cells as assessed using a phospho-Thr389–
specifi c antibody (Fig. 6 B). Rapamycin inhibited the TGF-β–
induced phosphorylation of S6K1 (Fig. 6 B), confirming 
activation of the mTOR pathway by TGF-β during TGF-β–
induced EMT. The rapamycin-induced decrease in S6K1 phos-
phorylation in the absence of TGF-β may refl ect the autocrine 
TGF-β stimulation. Consistent with our results with NMuMG 
cells (Fig. 5), rapamycin did not inhibit the TGF-β–induced 
EMT phenotype in HaCaT cells (Fig. 6 C). It should be noted 
that the TGF-β–induced phosphorylation of S6K1 as assessed 
using a phospho-Thr389–specifi c antibody was not restricted to 
NMuMG and HaCaT cells, which undergo EMT in response to 
TGF-β, but also occurred in C2C12 mouse myoblasts, NRK-
49F rat kidney fi broblasts, and 3T3-F442A mouse preadipocytes 
(unpublished data).
Consistent with the results of NMuMG cells, in HaCaT 
cells, TGF-β induced an increase in protein synthesis of 	60% 
after 48 h, whereas no difference was observed after 24 h (Fig. 
6 D), and induced an increase in cell size of 	50% after 72 h 
(Fig. 6 E), whereas no difference was observed after 48 h (not 
depicted). The TGF-β–induced increases in protein synthesis and 
cell size were inhibited by rapamycin (Fig. 6, D and E). Thus, as 
in NMuMG cells, mTOR activation is required for the TGF-β–
induced increases in protein synthesis and cell size but does not 
affect the TGF-β–induced EMT phenotype in HaCaT cells.
Rapamycin inhibits the enhanced migration 
and adhesion of NMuMG cells associated 
with TGF-𝛃–induced EMT
Besides inducing the phenotypic characteristics of EMT, TGF-β 
treatment of NMuMG cells also results in behavioral changes that 
are associated with EMT and are important aspects of TGF-β’s 
stimulatory role in tumorigenesis, such as an increase in cell 
motility and invasion (Bakin et al., 2000; Zavadil and Bottinger, 
2005; Thiery and Sleeman, 2006). To evaluate whether the 
mTOR pathway plays additional roles in the EMT process of 
NMuMG cells in addition to its effect on protein content and 
cell size, we examined the effect of rapamycin on NMuMG 
cells treated with TGF-β to induce EMT.
We fi rst examined the effect of rapamycin on the increased 
motility of cells in response to TGF-β using the monolayer 
wound assay (Pilkington et al., 1997). Thus, NMuMG cells were 
treated with or without TGF-β in the presence or absence of rapa-
mycin for 48 h, at which time all TGF-β–treated cells had under-
gone EMT. At that time, the cell monolayers were replenished 
with fresh medium and wounded with a pipette tip, and closing 
of the wound as a result of cell migration was analyzed by time-
lapse microscopy (Fig. 7 A and Videos 3 and 4, available at 
http://www.jcb.org/cgi/content/full/jcb.200611146/DC1). After 
12 h, cells that had been treated with TGF-β in the absence of 
rapamycin and had undergone EMT showed a 77% wound closure. 
In contrast, cells that were not treated with TGF-β and thus had 
maintained their epithelial phenotype showed a 56% wound 
closure (Fig. 7 B). Exposure to rapamycin concomitantly with 
TGF-β treatment reduced the wound closure of cells that had 
undergone EMT from 77 to 42%. In cells that had not been ex-
posed to TGF-β and thus had maintained their epithelial pheno-
type, rapamycin reduced the wound healing from 56 to 47% 
(Fig. 7 B). We also measured the migration speed of the cells in 
this experiment. We found that treatment with rapamycin con-
comitantly with TGF-β treatment and consequent EMT reduced 
the migration rate from 11.9 ± 1.5 to 6.5 ± 1.6 μm/h for cells 
that had been exposed to TGF-β.
We also measured the effect of rapamycin treatment with 
or without TGF-β on the migration of cells toward 10% FBS 
in transwell chambers (Pilkington et al., 1997). Confi rming the 
monolayer wound-healing results, rapamycin reduced the en-
hanced migration of cells that were treated with TGF-β to a 
level that is comparable with that of NMuMG cells that were not 
treated with TGF-β and therefore had maintained their epithelial 
phenotype. This effect was apparent at 24 h after initiation of the 
transwell migration assay but not at 6 h (Fig. 7 C). We conclude 
that activation of the mTOR pathway in response to TGF-β 
plays an essential role in the increased motility and migration of 
cells that have undergone EMT in response to TGF-β.
Migration involves discrete phases of adhesion and de-
adhesion (Angers-Loustau et al., 1999). Therefore, we examined 
whether rapamycin treatment affected the adhesion of cells to 
the culture plates. In this assay, cells were treated with or with-
out TGF-β in the presence or absence of rapamycin for 48 h 
(as for the wound-healing and migration assays), dissociated 
using trypsin, and seeded back in plastic culture plates. After 
30 min, nonadherent cells were removed by washing, and the 
adhered cells were released from the plastic and counted. Cells 
that were treated with TGF-β and thus had EMT conversion 
showed increased adhesion. In contrast, cells that had been 
treated with rapamycin together with TGF-β showed reduced 
adhesion (Fig. 7 D). Thus, inhibition by rapamycin of the in-
creased cell motility and migration in response to TGF-β is as-
sociated with (and likely, in part, is the result of) effects of 
rapamycin on the TGF-β–induced increase in cell adhesion.
Rapamycin decreases the invasive behavior 
of NMuMG cells after TGF-𝛃–induced EMT
Because rapamycin inhibited the migration of NMuMG cells 
that have undergone TGF-β–induced EMT, we also tested its 
effect on the invasive behavior of these cells. We used a stan-
dard in vitro invasion assay in which cells migrate through 
Matrigel and through the pores of a nitrocellulose fi lter toward 
10% serum and are then counted (Albini et al., 2004). Cells that 
had undergone EMT showed a much higher level of invasive 
behavior than those that had not been exposed to TGF-β and 
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thus had not undergone EMT (Fig. 8, A and B). In contrast, the 
addition of rapamycin concomitantly with TGF-β treatment to 
induce EMT resulted in a much lower level of invasion than 
cells that underwent TGF-β–induced EMT in the absence of 
rapamycin. In fact, the invasiveness of the TGF-β/rapamycin-
treated cells was similar to that of the NMuMG cells that were 
not exposed to TGF-β and did not undergo EMT. Therefore, we 
conclude that rapamycin inhibits the TGF-β–induced invasion 
associated with cells that have undergone EMT in response to 
TGF-β and, thus, that activation of the mTOR pathway by 
Figure 6. TGF-𝛃 activates the mTOR pathway during EMT in HaCaT cells. (A) Cells were treated or not treated with TGF-β for 72 h before photography. 
Original magnifi cation was 20×. (B) HaCaT cells were pretreated with or without rapamycin for 1 h, and TGF-β was added or not added to the medium 
for 1 h. Cell lysates were separated by SDS-PAGE and immunoblotted (IB) with phospho-S6K1 antibody. The fi lter was then stripped and reblotted with 
S6K1 antibody. (C) Cells were treated with or without rapamycin for 1 h, and TGF-β was added or not added to the medium. After 72 h, the cells were 
stained for F-actin and E-cadherin. DAPI was used to stain the nuclei. Original magnifi cation was 100×. (D) Cells were pretreated without or with rapamy-
cin for 1 h, and TGF-β was added or not added to the medium. After 24 and 48 h, the cells were trypsinized, and the cell number was determined. The total 
protein content normalized for cell number is shown relative to untreated cells. One experiment out of two independent experiments is shown with SD (error 
bars) for triplicates. (E) Cells were pretreated without or with rapamycin for 1 h, and TGF-β was added or not added to the medium for 72 h. The size distri-
bution of cells in G1 phase was determined by fl ow cytometry using the forward scatter (FSC) parameter. Quantifi cation of the FSC normalized to untreated 
cells shows relative mean values of one experiment out of two with SD for triplicates. Bars (A), 50 μm; (C) 10 μm.
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TGF-β plays an essential role in the increased invasive behavior 
of NMuMG cells with TGF-β–induced EMT.
Discussion
Although TGF-β signaling plays an important role as a tumor 
suppressor pathway, increased TGF-β expression by tumor 
cells is an important hallmark in cancer progression, as it con-
tributes through autocrine and paracrine mechanisms to tumor 
development, invasion, and metastasis (Derynck et al., 2001; 
Bierie and Moses, 2006). A key role of TGF-β in cancer pro-
gression results from its ability to induce EMT, which confers 
not only changes in cell phenotype but also enhances cell mi-
gration and invasion (Zavadil and Bottinger, 2005; Thiery and 
Sleeman, 2006). Using NMuMG epithelial cells, which are the 
commonly used model for TGF-β–induced EMT (Miettinen 
et al., 1994; Thuault et al., 2006), and human HaCaT cells that also 
undergo EMT in the presence of TGF-β (Zavadil et al., 2001), 
we found that the phenotypic changes in response to TGF-β are 
accompanied by an increase in cell size and protein content. 
We also showed that TGF-β activates the mTOR pathway via 
PI3K and Akt and that its activation is responsible for the effect 
of TGF-β on cell size and protein synthesis. Thus, our results 
demonstrate that in addition to regulating transcription through 
Smads, TGF-β can induce enhanced translation by inducing 
phosphorylation of the major targets of mTOR, S6K1, and 
4E-BP1. Finally, we show that blocking the mTOR pathway 
during TGF-β–induced EMT decreases the migration and invasion 
of the cells that have undergone EMT.
Increased cell size and protein synthesis 
during TGF-𝛃–induced EMT
During cancer progression, changes in the regulation of protein 
synthesis have been shown to occur. In several types of cancers, 
Figure 7. Effect of rapamycin on migration and 
adhesion of NMuMG cells after TGF-𝛃–induced 
EMT. (A) Cells were treated with or without ra-
pamycin for 1 h, and TGF-β was added or not 
added to the medium for 48 h. The cell mono-
layer was then scratched to create a wound, 
and the migration of the cells was observed by 
time-lapse microscopy and photography at 0 
and 12 h after wounding. Original magnifi ca-
tion was 10×. See Videos 3 and 4 (available 
at http://www.jcb.org/cgi/content/full/jcb
.200611146/DC1. (B) The percentage of 
wound healing was calculated from the mean 
of eight wound widths per condition with SD 
(error bars) measured at 12 h. One represen-
tative experiment out of three independent 
experiments is shown (*, P < 0.05; **, P < 
0.01). (C) Cells were treated with or without 
rapamycin for 1 h, and TGF-β was added or 
not added to the medium. After 36 h, the fl uor-
ophore DiI was added for an additional 12 h. 
The cells were then trypsinized and placed in 
transwell fi lter chambers. Fluorescent measure-
ments of migration of DiI-labeled cells through 
the transwell membrane were taken at 6 and 
24 h. The result shows one representative ex-
periment out of two independent experiments 
with SD for triplicates. (D) Cells were treated 
with or without rapamycin for 1 h, and TGF-β 
was added or not added to the medium. After 
48 h, the cells were trypsinized and reseeded 
on plastic culture plates, and nonadherent 
cells were removed by washing the plates with 
PBS at 30 min after reseeding. The number of 
adherent cells was determined. One represen-
tative experiment out of two independent 
 experiments is shown with SD for triplicates 
(**, P < 0.01). Bar, 200 μm.
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translation initiation and protein synthesis are up-regulated 
through cell-autonomous changes in the translation machinery, 
whereas in other scenarios, enhanced levels of c-myc or increased 
IGF-1 secretion and associated autocrine responses are thought 
to lead to enhanced cell size and protein synthesis (Ruggero and 
Pandolfi , 2003). In turn, increases in cell size and protein syn-
thesis enhance the proliferation of cancer cells because the con-
trol of protein synthesis and cell proliferation are intimately 
linked (Fingar and Blenis, 2004). Increased TGF-β expression 
by tumor cells was hitherto seen to contribute to cancer progres-
sion through its ability to induce EMT and through paracrine 
effects on the tumor microenvironment (Derynck et al., 2001; 
Bierie and Moses, 2006). The increased cell size and protein 
synthesis induced by TGF-β concomitantly with EMT is likely 
to represent another important contributing factor through 
which TGF-β stimulates cancer progression.
The TGF-β–induced increase in cell size during EMT is 
consistent with several other observations of cell size regulation 
by TGF-β family proteins. In Caenorhabditis elegans, TGF-β 
family signaling regulates body size (Krishna et al., 1999; Suzuki 
et al., 1999). In vertebrates, bone morphogenetic protein signal-
ing participates in chondrocyte hypertrophy (Leboy et al., 1997; 
Volk et al., 1998), and myostatin/growth and differentiation 
factor-8 acts as a negative regulator of the skeletal muscle mass 
through effects on the size and number of myofi bers (McPherron 
et al., 1997). Under pathological conditions, TGF-β can increase 
smooth muscle mass of the bronchi in a mouse model to study 
asthma (Goldsmith et al., 2006) and is also thought to be involved 
in the hypertrophy of cardiomyocytes (Brand and Schneider, 
1995). We now present evidence that TGF-β induces increased 
cell size and protein content during EMT.
TGF-𝛃 activates the mTOR pathway 
during EMT
In studying the mechanisms of the TGF-β–induced cell size in-
crease, we found that TGF-β rapidly activates mTOR and that this 
Figure 8. Effect of rapamycin on the invasion of NMuMG 
cells after TGF-𝛃–induced EMT. NMuMG cells were treated 
with or without rapamycin for 1 h, and TGF-β was added or 
not added to the medium. After 48 h, cells were trypsinized 
and placed in Matrigel-coated transwell fi lter chambers and 
incubated for 24 h. The noninvading cells were removed from 
the upper surface of the membrane, cells that adhered to the 
lower surface were fi xed, and the nuclei were stained with 
DAPI. (A) Photography of the DAPI staining using fl uorescence 
microscopy. The result shows a fi eld of one fi lter per condition 
in one representative experiment out of three independent ex-
periments. Original magnifi cation was 10×. (B) The DAPI-
stained nuclei were counted in four fi elds per fi lter in triplicate 
in one representative experiment out of three independent ex-
periments (*, P < 0.05). The horizontal bars represent the cell 
number mean of 12 fi elds for each condition. Bar, 200 μm.
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activation leads to the phosphorylation of two major mTOR tar-
gets, S6K1 and 4E-BP1. Growth factors such as insulin and IGF-1 
that signal through receptor tyrosine kinases activate mTOR 
through PI3K and Akt activation (Hay and Sonenberg, 2004). 
Although TGF-β acts through serine/threonine kinase receptors, 
we found that TGF-β rapidly induces Akt phosphorylation. PI3K, 
Akt, mTOR, S6K1, and 4E-EBP1 are linked in one pathway 
activated by TGF-β, and this is supported by several observa-
tions. First, wortmannin and LY294002, which are two inhibitors 
of PI3K, prevent TGF-β–induced Akt phosphorylation. In 
addition, wortmannin, the mTOR inhibitor rapamycin, and a 
dominant-negative version of Akt all inhibit TGF-β–induced 
S6K1 phosphorylation. Finally, inhibition of the TβRI kinase us-
ing SB431542 prevents TGF-β–induced Akt phosphorylation. 
Therefore, we conclude that in response to TGF-β, TβRI acti-
vates the pathway that connects PI3K and Akt with mTOR, S6K1, 
and 4E-BP1. These results are consistent with the recent observa-
tion that the catalytic subunit of PI3K can interact with TβRI, lead-
ing to PI3K activation upon TGF-β stimulation (Yi et al., 2005).
In accordance with the induction of increased cell size 
through the mTOR pathway, rapamycin prevented the TGF-β–
induced increase in cell size during EMT without affecting the 
associated morphological changes. Thus, in the presence of rapa-
mycin, NMuMG and HaCaT cells underwent apparent EMT in 
response to TGF-β but were smaller than those cells that were not 
exposed to rapamycin. These results suggest that the rapamycin-
sensitive mTORC1 pathway is not involved in the EMT phenotype 
itself, which is in agreement with other observations that rapamy-
cin does not affect EMT (Bakin et al., 2000; Aguilera et al., 2005). 
These data also suggest that activation of PI3K and Akt leading 
to mTOR activation may not be involved in the morphological 
changes of EMT. This would be consistent with the inability of 
wortmannin to block EMT (Bakin et al., 2000).
The inhibition of TGF-β–induced S6K1 and 4E-BP1 
phosphorylation by rapamycin suggests that TGF-β induces in-
creased cell size through its effects on the rapamycin-sensitive 
mTORC1. Thus, activation of S6K1 by TGF-β is expected to 
enhance the translational machinery, and induction of 4E-BP1 
phosphorylation leads to the enhanced translation of capped 
mRNAs (Hay and Sonenberg, 2004). Although S6K1 and 4E-BP1 
appear to act as effectors in the increased protein translation 
upon TGF-β treatment, the effect of TGF-β on mTORC2 is 
currently unknown. mTORC2 regulates the actin cytoskeleton, 
and its activity may be regulated through PKCα and the small 
GTPases Rho and Rac (Wullschleger et al., 2006). Because 
EMT involves dramatic changes in the cytoskeleton that result 
from the activities of small GTPases, it will be important to 
evaluate whether TGF-β signaling regulates the activity of this 
complex and whether such regulation may play a role in EMT.
Another level of regulation by TGF-𝛃: 
translational control
TGF-β family proteins signal through Smads, which combine 
with DNA sequence-specifi c transcription factors to activate or 
repress transcription (Feng and Derynck, 2005; Massagué et al., 
2005). The Smad pathway, which, in the case of TGF-β, is 
mediated by Smad2 and Smad3 in combination with Smad4, is 
considered to be the major TGF-β family signaling pathway 
and accounts for the many changes in gene expression observed 
in response to TGF-β family proteins. TGF-β–induced non-
Smad pathways have been identifi ed and lead to the activation 
of Erk and JNK MAPK or RhoA, but how these pathways are 
activated in response to TGF-β is not well understood (Derynck 
and Zhang, 2003; Moustakas and Heldin, 2005). In TGF-β–
induced EMT, Smad signaling represents an essential pathway 
that confers changes in gene expression through cooperation 
with transcription factors such as Snail, Slug, and/or Id (Zavadil 
and Bottinger, 2005). Non-Smad signaling in response to TGF-β 
(e.g., activation of RhoA) also contributes to EMT and is impor-
tant for the associated cytoskeletal and phenotypic changes 
(Bhowmick et al., 2001). Our results now show that TGF-β can 
increase protein synthesis in EMT through the mTOR pathway, 
leading to the regulation of S6K1 and 4E-BP1 activities. The 
activation by TGF-β of a pathway that leads directly to increased 
protein synthesis stands in contrast with the changes in gene 
transcription through the Smad pathway (Fig. 9). Thus, in addition 
to changes in gene expression, TGF-β signaling through mTOR 
leads to the enhanced translation of proteins that contribute to 
the behavior of cells that undergo EMT. Accordingly, studies 
using rapamycin have implicated mTOR in the regulation of 
collagen synthesis (Shegogue and Trojanowska, 2004). A char-
acterization of the relative changes in protein levels that are in-
dependent of changes in gene expression and can be blocked by 
rapamycin will provide insight into the contribution of mTOR 
signaling to the cell’s response to TGF-β.
Rapamycin decreases the invasive behavior 
of the cells after TGF-𝛃–induced EMT
Although rapamycin did not block the TGF-β–induced EMT 
morphology, it inhibited the increased migration and invasion 
of NMuMG cells that accompanies EMT. These data suggest 
that mTORC1 plays a role in defi ning the migration and inva-
sion of cells that have undergone EMT in response to TGF-β. 
Thus, rapamycin not only blocks the increased cell size but also 
Figure 9. Divergent TGF-𝛃 signaling pathways induce transcriptional 
regulation through Smads and translational regulation through the 
mTORC1 pathway.
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the invasive behavior of cells with EMT without affecting the 
EMT-associated morphological changes. The mechanisms 
through which rapamycin inhibits invasion remain to be clari-
fi ed, although the induction of expression of the metalloprotein-
ase ADAM-12 and the metalloproteinase inhibitor TIMP-3 by 
TGF-β was recently reported to be inhibited by rapamycin 
(Le Pabic et al., 2005; Qureshi et al., 2007). Perhaps the mTOR 
pathway selectively regulates the translation of matrix metallo-
proteases and other proteins that allow for increased invasion in 
response to TGF-β. Our observation that rapamycin inhibits the 
migration and invasion of cells after TGF-β–induced EMT 
agrees with recent observations that rapamycin inhibits the in-
duced motility of some cancer cells (Liu et al., 2006).
As PI3K and mTOR activities are commonly up-regulated 
in various cancers, PI3K inhibitors and rapamycin analogues are 
investigated as inhibitors of cancer progression in preclinical 
and clinical trials (Faivre et al., 2006; Hynes and Boulay, 2006; 
Smolewski, 2006). Our observations on the activation of mTOR 
signaling and the increase of cell size in response to TGF-β 
during EMT may have considerable clinical relevance. Indeed, 
increased autocrine TGF-β expression and responsiveness lead-
ing to TGF-β–induced EMT are considered to be important 
initiators of the invasive behavior of cancers during cancer pro-
gression. Our fi ndings that TGF-β–induced EMT is accompa-
nied by increased cell size and that the increased cell size and 
the EMT-associated increase in invasive behavior are mediated 
by increased mTOR signaling in response to TGF-β suggest 
that rapamycin analogues can be used to antagonize some key 
features of EMT that contribute to cancer progression.
Materials and methods
Cell culture, treatments, and transfection
NMuMG and HaCaT cells were cultured in DME with glucose (4.5 g/liter) 
and 10% FBS (Equitech-Bio, Inc.), 100 U/ml penicillin, and 100 mg/ml 
streptomycin. The medium to culture NMuMG cells was supplemented with 
10 μg/ml insulin (Sigma-Aldrich). Images of the cells were captured at 
room temperature using a Spot RT slider camera (2.3.0; Diagnostic Instru-
ments) on a microscope (Axiovert S-100; Carl Zeiss MicroImaging, Inc.) 
with a 40× Hoffmann modulation objective and Openlab software (Impro-
vision) or a camera (D2x; Nikon) on a microscope (Diaphot; Nikon) with 
a 20× NA 0.4 air objective and Photoshop software (Adobe).
Cells were stimulated with 2–10 ng/ml TGF-β (PeproTech) for 10 min 
to 48 or 72 h. After incubation in a medium without insulin overnight, 
control cells were treated with 5 μg/ml insulin for 1 h to activate mTOR. To 
inhibit signaling effectors, the cells were treated with 100 nM rapamycin 
and 100 nM wortmannin (Calbiochem) or 5 μM SB431542 and 10 μM 
LY294002 (Sigma-Aldrich) for 1 h before TGF-β or insulin treatment, and 
DMSO was used as a control. To inhibit Akt signaling, cells were trans-
fected using LipofectAMINE PLUS (Invitrogen) with a plasmid expressing 
an Akt mutant in which Ser473 and Thr308 were replaced by alanines 
(Stokoe et al., 1997).
Immunofl uorescence microscopy
Cells were fi xed with 4% PFA for 30 min, permeabilized in 2% PFA and 
0.2% Triton X-100 for 10 min, and incubated in a PBS and 3% BSA block-
ing solution for 1 h. The slides were incubated for 2 h with anti–E-cadherin, 
anti–N-cadherin (BD Biosciences), anti–ZO-1 (Zymed Laboratories), or anti-
fi bronectin (Sigma-Aldrich) diluted (1:400, 1:500, 1:200, or 1:400, re-
spectively) in PBS and 3% BSA and were stained for 1 h with FITC-conjugated 
secondary antibody (1:500; Invitrogen) or rhodamine-conjugated phalloi-
din (1:500; Invitrogen) to visualize actin fi laments. The slides were incu-
bated with DAPI (1:10,000; Sigma-Aldrich) for 10 min to stain nuclei. 
After mounting the slides (Cytoseal 280 mounting medium; Richard-Allan 
Scientifi c), the cells were viewed at room temperature by epifl uorescence 
microscopy with a microscope (Axiophot; Carl Zeiss MicroImaging, Inc.) 
using a 100× NA 1.3 oil objective (Carl Zeiss MicroImaging, Inc.) or a 
microscope (Eclipse TE2000-E; Nikon) using a 100× NA 1.49 oil objective 
(Nikon), and images were analyzed using Spot (Diagnostic Instruments), 
NIS-Elements (Nikon), and Photoshop software (Adobe).
Flow cytometry
The cells, which were treated or not treated for 48 h with rapamycin or 
SB431542 with or without TGF-β, were trypsinized and resuspended in 
PBS containing 3% FBS, and 7 μg/ml Hoechst no. 33342 (Sigma-Aldrich) 
was added for 45 min. 1 μg/ml propidium iodide (Sigma-Aldrich) was 
added just before fl ow cytometry, which was performed with a sorter/
analyzer SE three-laser system (FACSVantage; Becton Dickinson). The cell 
cycle and cell size were analyzed with CellQuest (BD Biosciences) and 
WinMDI 2.8 software.
Protein content and metabolic labeling
To measure protein content, cells were trypsinized, and the cell number 
was determined. The cells were lysed in radioimmunoprecipitation assay 
buffer with protease inhibitors, and the protein content was quantifi ed us-
ing protein assay (Bio-Rad Laboratories) and normalized to cell number.
For metabolic labeling of proteins, cells were preincubated in 
methionine–cysteine-free DME, and 150 μCi/ml [35S]methionine–[35S]cysteine 
(PerkinElmer) was added for 3 h. The cells were lysed in radioimmuno-
precipitation assay buffer with protease inhibitors. After centrifugation 
for 10 min at 4°C, 1:10 of the supernatant was precipitated with 300 μl of 
20% trichloroacetic acid on ice for 20 min. After fi ltration on 0.22-μm GS 
Millipore membranes, the precipitated 35S-labeled protein was quantifi ed 
and normalized against cell number.
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer with protease 
and phosphatase inhibitors. Proteins were quantifi ed using protein assay 
(Bio-Rad Laboratories), and 20 μg of protein was separated by SDS-PAGE 
and transferred to 0.2 μm nitrocellulose membrane. Membranes were 
blocked in TBS, 0.1% Tween 20, and 5% BSA for 2 h before overnight in-
cubation with primary antibody diluted 1:1,000 in TBS, 0.1% Tween 20, 
and 5% BSA. Antibodies to phospho-S6K1 (Thr389), phospho–4E-BP1 
(Ser65), phospho-mTOR (Ser2448), mTOR, phospho-Akt (Ser473), Akt, 
and phospho-Smad3 (Ser433/435)/Smad1 (Ser463/465) were obtained 
from Cell Signaling Technology. Antibodies to S6K1, 4E-BP1, and Smad3 
were purchased from Santa Cruz Biotechnology, Inc., Bethyl Laboratories, 
and Zymed Laboratories, respectively. Antibody to α-tubulin was purchased 
from Sigma-Aldrich and diluted 1:4,000 in TBS, 0.1% Tween 20, and 5% 
BSA. The membranes were incubated for 1 h in HRP-conjugated secondary 
antibody diluted at 1:2,000–1:10,000 in TBS and 0.1% Tween 20. Immuno-
reactive protein was detected using ECL (GE Healthcare) and BioMax 
fi lm (Kodak).
Migration assay
Cell monolayers were wounded with a plastic tip at 48 h after the initiation 
of treatment (Pilkington et al., 1997). The migration was followed for 12 h 
at 37°C and photographed using a Spot RT slider camera (2.3.0; Diagnos-
tic Instruments) mounted on a microscope (Axiovert S-100; Carl Zeiss Micro-
Imaging, Inc.) with a 10× Hoffmann modulation objective and Openlab 
software (Improvision).
For cell migration in the transwell assay (Pilkington et al., 1997), 
cells were labeled with 5 μg/ml of the fl uorophore DiI (Invitrogen) for 12 h 
starting at 36 h after the initiation of treatment. The cells were then trypsin-
ized, and 50,000 cells suspended in DME and 0.2% FBS were added to 
transwell inserts (8-μm pore size; Falcon HTSF Fluoroblok inserts; Becton 
Dickinson), held in 24-well companion plates with DME and 10% FBS, and 
incubated for 6–24 h. Migration of cells to the lower culture plate was as-
sessed by the fl uorescence of DiI using a fl uorimeter (SpectraMax M5; 
Molecular Devices).
Adhesion assay
Cells were trypsinized and seeded onto multiwells for 30 min. Unattached 
cells were removed by washing twice with PBS, and the attached cells 
were counted after trypsinization.
Invasion assay
Cells were trypsinized, and 50,000 cells resuspended in DME with 0.2% 
FBS were added to rehydrated Matrigel-coated inserts (BioCoat Matrigel In-
vasion Chamber; Becton Dickinson) and placed in 24-well companion plates 
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with DME and 10% FBS (Albini et al., 2004). After 24 h, the cells and Matri-
gel in the upper chambers were removed using a cotton tip. The fi lters were 
fi xed in methanol for 5 min at −20°C, incubated in DAPI (1:5,000; Sigma-
Aldrich) for 10 min, and mounted (Cytoseal 280 mounting medium; Richard-
Allan Scientifi c). The invading cells were counted at room temperature using 
an epifl uorescence microscope (Axiophot; Carl Zeiss MicroImaging, Inc.) 
with a 10× NA 0.3 air objective, and images were analyzed using Spot 
(Diagnostic Instruments) and Photoshop software (Adobe).
Online supplemental material
Time-lapse video microscopy (Fig. 1) of untreated or TGF-β–treated NMuMG 
cells is shown in Videos 1 and 2, respectively, to show changes in morphol-
ogy and cell size during EMT. Images were captured at 20-min intervals for 
36 h at 37°C in growth medium. Time-lapse video microscopy (Fig. 7) of a 
wound-healing experiment of TGF-β–treated NMuMG cells in the absence 
or presence of rapamycin is shown in Videos 3 and 4, respectively, to 
show cell migration after TGF-β–induced EMT. Images were captured at 
15-min intervals for 12 h at 37°C in growth medium. Images were cap-
tured using a Spot RT slider camera (2.3.0; Diagnostic Instruments) mounted 
on a microscope (Axiovert S-100; Carl Zeiss MicroImaging, Inc.) with a 
10× Hoffmann modulation objective and operated using Openlab soft-
ware (Improvision). Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200611146/DC1.
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